
Hand & Wrist
AAHS 2015: Exparel vs. Marcaine for postoperative analgesia in outpatient wrist procedures
28 patients were randomized to recieve either Exparel (bupivacaine extended-release liposome) or Marcaine (bupivacaine) following either carpometacarpal arthroplasty (CMCA) or proximal row carpectomy (PRC). The purpose of the study was to determine whether Exparel was effective in reducing pain, reducing opioid use and opioid side effects, and improving long-term hand function when compared to Marcaine. Outcomes that were assessed included the Numeric Rating Scale (NRS), number of opioids taken, Overall Benefit of Analgesia Scale (OBAS), and QuickDASH. On the first postoperative day, pain scores and opioid consumption were reported to be significantly lower in the Exparel group compared to the Marcaine group. No significant between-group differences were observed beyond the first postoperative day in terms of pain and function scores, nor in rate of side effects.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.